Vaccines Unit Shines For GSK In 3Q
Executive Summary
GlaxoSmithKline's vaccine's business, which has been under the spotlight this week following a US regulatory submission for its highly anticipated shingles vaccines, Shingrix, has come out shining in the third quarter – setting the stage for a strong full-year readout.
You may also be interested in...
Stayin’ Alive: GSK Sees Options For Brand Advair In A Post-Generic World
Payers might be open to keeping the Advair brand on formulary even if a generic becomes available, because GSK has a portfolio of respiratory drugs to leverage in negotiations, CEO Andrew Witty said during the company’s third quarter conference call.
Stayin’ Alive: GSK Sees Options For Brand Advair In A Post-Generic World
Payers might be open to keeping the Advair brand on formulary even if a generic becomes available, because GSK has a portfolio of respiratory drugs to leverage in negotiations, CEO Andrew Witty said during the company’s third quarter conference call.
Infographic: Top 100 Pharma Companies
The Scrip 100 universe gathers FY2021 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.